ERG and prostate carcinoma: Functional, genetic, and biochemical studies revealed that P199 contributes to the ERG-NCoR-HDAC3 interaction, thereby highlighting HDAC3 as a potential therapeutic target for ERG-mediated leukemias and, possibly, other malignancies such as prostate cancer.